Heparin for oral use: preliminary studies.
作者信息
Horwitz O, Johnson W T, Sayen J J, Roberts B, Whereat A F
机构信息
Department of Medicine (Cardiovascular Section), University of Pennsylvania, Philadelphia.
出版信息
Trans Am Clin Climatol Assoc. 1993;104:94-102; discussion 102-3.
Abstract
摘要
相似文献
1
Heparin for oral use: preliminary studies.口服肝素：初步研究。
Trans Am Clin Climatol Assoc. 1993;104:94-102; discussion 102-3.
2
Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.肝素钠和抗凝血酶III浓度对犬活化部分凝血活酶时间的影响。
Am J Vet Res. 1985 Jul;46(7):1460-2.
3
Absence of drug interaction between heparin and nitroglycerin. Randomized placebo-controlled crossover study.肝素与硝酸甘油之间不存在药物相互作用。随机安慰剂对照交叉研究。
Arch Intern Med. 1990 Oct;150(10):2117-9.
4
Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment.体外循环期间的肝素抵抗。肝素预处理的作用。
J Thorac Cardiovasc Surg. 1983 Mar;85(3):346-53.
5
Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
Am J Vet Res. 1982 Aug;43(8):1473-7.
6
[Influence of bigumal on the blood coagulation system and on the anticoagulant effect of heparin].[双香豆素对血液凝固系统及肝素抗凝作用的影响]
Farmakol Toksikol. 1986 Nov-Dec;49(6):43-5.
7
Characterization of a new potent heparin. 7th communication: A comparative study of a new potent heparin in human after i.v. application.
Arzneimittelforschung. 1981;31(2):386-8.
8
[Heparin management by activated coagulation time during cardiopulmonary bypass].[体外循环期间通过活化凝血时间进行肝素管理]
Kyobu Geka. 1981;34(12):934-7.
9
[Heparin level and coagulation potential after subcutaneous injection of 7500 international units of heparin calcium].
Dtsch Med Wochenschr. 1984 Jun 22;109(25):993-6. doi: 10.1055/s-2008-1069313.
10
Morning vs evening effects of intrapulmonary administration of heparin in healthy men.健康男性肺内注射肝素的早晨与傍晚效应
Int J Clin Pharmacol Ther Toxicol. 1992 Oct;30(10):400-4.
引用本文的文献
1
Emerging for non-invasive heparin delivery systems: recent advances, barriers, solutions, and applicability.新兴的非侵入性肝素递送系统：最新进展、障碍、解决方案及适用性
Saudi Pharm J. 2025 Jun 12;33(3):17. doi: 10.1007/s44446-025-00022-6.
2
The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.生物活性大分子的非侵入性递送研究：聚焦于肝素
J Control Release. 2006 Jun 28;113(2):91-101. doi: 10.1016/j.jconrel.2006.04.008. Epub 2006 Jun 14.
本文引用的文献
1
Blood lipids and human atherosclerosis. II. The influence of heparin upon lipoprotein metabolism.血脂与人类动脉粥样硬化。II. 肝素对脂蛋白代谢的影响。
Circulation. 1951 Nov;4(5):666-73. doi: 10.1161/01.cir.4.5.666.
2
Unstable angina, myocardial infarction, heparin and death: medium dose heparin (not exceeding 20,000 units/day) in the treatment of patients with acute coronary event--first year and long-term comparative mortality.不稳定型心绞痛、心肌梗死、肝素与死亡：中等剂量肝素（不超过20000单位/天）治疗急性冠状动脉事件患者——首年及长期比较死亡率
Trans Am Clin Climatol Assoc. 1983;94:141-53.
3
Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome.
Lancet. 1981 Jun 6;1(8232):1225-8. doi: 10.1016/s0140-6736(81)92399-0.
4
Heparin and atherosclerosis: an investigative report on the treatment of atherosclerosis.肝素与动脉粥样硬化：关于动脉粥样硬化治疗的调查报告
Biomed Pharmacother. 1990;44(6):303-6. doi: 10.1016/0753-3322(90)90133-t.
5
Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000.来自内皮细胞的关于肝素和硫酸葡聚糖8000胃吸收的证据。
J Lab Clin Med. 1991 Feb;117(2):122-30.
6
Pharmacodynamics, clinical indications, and adverse effects of heparin.肝素的药效学、临床适应证及不良反应。
J Clin Pharmacol. 1992 Jul;32(7):584-96. doi: 10.1002/j.1552-4604.1992.tb05765.x.
7
Biologic actions of heparin.肝素的生物学作用。
Semin Hematol. 1977 Oct;14(4):427-40.
Zotero 插件